<--- Back to Details
First PageDocument Content
Nucleosides / Acute myeloid leukemia / Medicine / Chemotherapy regimens / Organofluorides / Oncology / Acute leukemia / Cytarabine
Date: 2014-12-17 16:45:05
Nucleosides
Acute myeloid leukemia
Medicine
Chemotherapy regimens
Organofluorides
Oncology
Acute leukemia
Cytarabine

AML Induction Protocol - Specialized

Add to Reading List

Source URL: txch.org

Download Document from Source Website

File Size: 112,90 KB

Share Document on Facebook

Similar Documents

The Dual E-selectin/CXCR4 Antagonist GMI-1359 Exerts Anti-leukemia Efficacy Against FLT3-ITDmutated Acute Myeloid Leukemia in A Patient-derived Xenograft Murine Model Mouse-1 Mouse-2

DocID: 1uSbg - View Document

A Phase I/II Study of GMI-1271, a Novel E-selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Previously Untreated Elderly Patients with Acute Myeloid Leukemia; Results to Date Dan

DocID: 1uJQ2 - View Document

Vascular E-Selectin Mediates Chemo-Resistance in Acute Myeloid Leukemia Initiating Cells Via Canonical Receptors PSGL-1 (CD162) and Hcell (CD44) and AKT Signaling Ingrid G Winkler, PhD1*, Johanna M Erbani, PhD student2*,

DocID: 1u5Xi - View Document

Regulatory Perspective: Acute Leukemia Clinical Endpoints Nancy S. Scher, MD, FACP DODP, CDER, FDA 1

DocID: 1tdCV - View Document

· ACUTE LYMPHOBL ASTIC LEUKEMIA · Incorporating Antibodies into Treatment Strategies for Acute Lymphoblastic Leukemia Nicholas J. Short, MD, and Elias Jabbour, MD

DocID: 1shAS - View Document